Patents for SolirisR INCLINE VILLAGE Nev

The Company does notundertake to update any forward looking statements.Sonic, the Sonic logo, Sonic Solutions, Roxio, the Roxio logo, Toast,Roxio Streamer, and Hollywood to Home are trademarks or registered trademarksowned by Sonic Solutions in the United States and/or other countries. Allother company or product names are trademarks of their respective owners and,in some cases, are used by Sonic Solutions under license. Specifications,pricing and delivery schedules are subject to change without notice.SOURCERoxioChris Taylor of Roxio, 1-408-367-5231, . Plus, his time in New York was limited, so I wouldn’t draw any certainties from it.His key is going to be keeping opponents driving the ball into the ground. From 2003-2008 he had just one season posting afly ball rate of under 40 percent, but last year saw the number fall to 34.8 percent. If he can maintain that the impact of the newYankee Stadium may not be huge, but I wouldn’t hold out hope for that.Left-handed hitters took him deep 14 times last season and considering the dimensions of Yankee Stadium, he could have problems.All it means is that you are going to have a pitcher with an ERA probably right around 4.00 to go along with plenty of strikeouts and wins. Is anyone really going to complain about that While he’s got to be downgraded a little bit, he’s still surely a pitcher that you want to own.As for the haul the Braves got, it’s underwhelming for 2010.

He’s a short-term fill-in, at best, even in five outfielder formats. There’s just no real power or speed potential.The bright spot is Vizcaino, though he is still a ways away from making an impact. He was ranked by Baseball America as the Yankees' third best prospect with a fastball that reaches 96 and a curveball that “is second only to A.J. Burnett’s in the organization.”He is just 19 years old, however, though he posted a 2.13 ERA and 52 strikeouts in 42 innings last season. He’s a name to watch, but he’s not about to make an impact any time soon.What are your thoughts on the deal How do you see Vazquez performing in the new Yankee Stadium Do you see any potential in what the Braves receivedPrevious Fantasy Impacts of Recent Transactions: Hermida to Boston Teahen for Fields & Getz Iwamura to Pittsburgh Hardy for Gomez Shoppach to Tampa Bay Wagner to Atlanta Polanco, Scutaro, Fox & Zaun Granderson-Scherzer-Jackson Blockbuster Millwood, Harden, Wolf & More Figgins, Lowell & More Lackey to the Red Sox Matsui, Cameron & Pierre Halladay/Lee Blockbuster This article is also featured on Alexion Licenses PDL's Queen et al.

Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan 5 /PRNewswire-FirstCall/ PDL BioPharma, Inc (Nasdaq:PDLI) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today jointly announced that the companies have entered into adefinitive license agreement and settlement agreement that resolve the legaldisputes between them relating to Alexion's humanized antibody, Soliris(R)(eculizumab) and PDL's patents known as the Queen et al. patents.Under the agreements announced today, PDL has granted Alexion a license undercertain claims in the Queen patent portfolio, and provided Alexion a covenantnot to sue in respect of other claims in the Queen patent portfolio, thuspermitting Alexion to commercialize Soliris for all indications under theQueen patents.In consideration of this license, Alexion will pay PDL $25million.No additional payments will be owed by Alexion to PDL under theQueen patents in respect of Soliris sales for any indication.As part of thesettlement, Alexion has confirmed that the Queen patent claims are valid andthat Soliris employs technology covered under the Queen patents.Further,Alexion has agreed not to challenge or assist other parties in challenging thevalidity of the Queen patents in the future.PDL's Queen patents are related to the humanization of antibodies.Soliriswas approved in the U.S. and European Union in 2007 as a treatment forpatients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare,debilitating and life-threatening blood disease.The use of Soliris as atreatment for other rare and severe disorders is in early stages ofinvestigation. Under the license agreement announced today, PDL has separately grantedAlexion the right to take a royalty-bearing license under PDL's Queen patentsto commercialize additional Alexion humanized antibodies that may be coveredby the Queen patents in the future.In the event that Alexion takes such alicense, Alexion will pay PDL a royalty of 4 of net sales of such non-Solirisproducts.Additional terms of the agreements were not disclosed."PDL helped revolutionize the development of therapeutic antibodies to treatpatients with previously untreatable and devastating conditions," said LeonardBell, M.D., Chief Executive Officer of Alexion John P.